Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform

Bibliographic Details
Main Authors:	Ahmad, Shamim, Mkrtichyan, Mikayel, Eid, Rasha Abu, Shrimali, Rajeev, Doroodchi, Atbin, Khleif, Samir N
Format:	Online
Language:	English
Published:	BioMed Central 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288341/

Similar Items

AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells
by: Abu Eid, Rasha, et al.
Published: (2014)

Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival
by: Juss, Jatinder K., et al.
Published: (2012)

The Phosphoinositide 3-Kinase Isoform PI3Kβ Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice
by: Győri, Dávid, et al.
Published: (2014)

The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas
by: Valkov, Andrej, et al.
Published: (2011)

Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo
by: Smith, Greg C., et al.
Published: (2012)

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
by: Sahin, I, et al.
Published: (2014)

Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma
by: Höland, Katrin, et al.
Published: (2014)

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia
by: Blunt, Matthew D., et al.
Published: (2015)

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine
by: Berrong, Zuzana, et al.
Published: (2014)

PI3K Pathway in NSCLC
by: Martinez-Martí, Alex, et al.
Published: (2012)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
by: Lonetti, Annalisa, et al.
Published: (2015)

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
by: Mkrtichyan, Mikayel, et al.
Published: (2013)

Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells
by: TIAN, FENG, et al.
Published: (2015)

Challenges in the clinical development of PI3K inhibitors
by: Massacesi, Cristian, et al.
Published: (2013)

More Paths to PI3Kγ
by: Stephens, Len, et al.
Published: (2013)

The Treatment of Activated PI3Kδ Syndrome
by: Tanya I. Coulter, et al.
Published: (2018-09-01)

PI3K inhibitors in inflammation, autoimmunity and cancer
by: Stark, Anne-Katrien, et al.
Published: (2015)

Hyper-activated PI3K-δ in immunodeficiency
by: Heurtier, Lucie, et al.
Published: (2015)

PI3K and AKT: Unfaithful Partners in Cancer
by: Faes, Seraina, et al.
Published: (2015)

PI3K/AKT Pathway and Brain Malformations
by: Rice, Gavin B., et al.
Published: (2015)

Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms
by: Conte, Enrico, et al.
Published: (2011)

Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor
by: Berenjeno, Inma M., et al.
Published: (2012)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX1
by: Iezzi, Alice, et al.
Published: (2016)

PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition
by: Zhao, Hua-Fu, et al.
Published: (2016)

Trim32 reduces PI3K–Akt–FoxO signaling in muscle atrophy by promoting plakoglobin–PI3K dissociation
by: Cohen, Shenhav, et al.
Published: (2014)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection
by: Pillinger, Genevra, et al.
Published: (2016)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
by: Liu, Xiaochuan, et al.
Published: (2016)

The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo
by: Ejeskär, Katarina, et al.
Published: (2015)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
by: Akinleye, Akintunde, et al.
Published: (2013)

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival
by: Abu Eid, Rasha, et al.
Published: (2015)

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy
by: Rajeev Shrimali, et al.
Published: (2017-08-01)

Disentangling weak and strong interactions in $$B\rightarrow K^{*}(\rightarrow K\pi )\pi $$ B → K ∗ ( → K π ) π Dalitz-plot analyses
by: Jérôme Charles, et al.
Published: (2017-08-01)

PI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide
by: Maurya, Akhilendra Kumar, et al.
Published: (2016)

Phosphoinositides signalling in cancer: Focus on PI3K and PLC
by: Raimondi, C., et al.
Published: (2012)

PI3K/AKT/mTOR Pathway in Angiogenesis
by: Karar, Jayashree, et al.
Published: (2011)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
by: Markman, Ben, et al.
Published: (2010)

Elevated PI3K signaling drives multiple Breast Cancer subtypes
by: Adams, Jessica R., et al.
Published: (2011)

INPP4B: the New Kid on the PI3K Block
by: Agoulnik, Irina U., et al.
Published: (2011)

PI3K: An Attractive Candidate for the Central Integration of Metabolism and Reproduction
by: Acosta-Martínez, Maricedes
Published: (2012)

Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma
by: Hafner, Christian, et al.
Published: (2012)